{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Vascular+Disorders&page=15", "query": { "condition": "Retinal Vascular Disorders", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 434, "total_pages": 44, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Vascular+Disorders&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Retinal+Vascular+Disorders&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T05:52:09.173Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00824824", "title": "Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glaucoma" ], "interventions": [ { "name": "Dorzolamide 2%-timolol 0.5%", "type": "DRUG" }, { "name": "Brimonidine 0.2%-0.5% timolol 0.5", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 21, "start_date": "2009-01", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00824824" }, { "nct_id": "NCT04704921", "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "AMD", "nAMD", "Wet Age-related Macular Degeneration", "wAMD", "Wet AMD", "CNV", "Neovascular AMD", "Neovascular Age-related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "ABBV-RGX-314", "type": "GENETIC" }, { "name": "Ranibizumab (LUCENTIS®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "GENETIC", "BIOLOGICAL" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 671, "start_date": "2020-12-29", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 89, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704921" }, { "nct_id": "NCT02296567", "title": "Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Age Related Macular Degeneration" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Control Group", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "East Florida Eye Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 80, "start_date": "2014-12", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2015-08-11", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 1, "location_summary": "Stuart, Florida", "locations": [ { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296567" }, { "nct_id": "NCT04976777", "title": "A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema" ], "interventions": [ { "name": "Updated DEX PS DDS Applicator", "type": "DEVICE" }, { "name": "Approved DEX PS DDS Applicator", "type": "DEVICE" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-10-12", "completion_date": "2022-02-09", "has_results": true, "last_update_posted_date": "2023-02-28", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 7, "location_summary": "Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "North Dartmouth", "state": "Massachusetts" }, { "city": "Independence", "state": "Missouri" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Abilene", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04976777" }, { "nct_id": "NCT01445899", "title": "PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Choroidal Neovascularization", "Diabetic Retinopathy", "Diabetic Macular Edema" ], "interventions": [ { "name": "PF-04523655 (Stratum I)", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "PF-04523655 (Stratum II)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Quark Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2012-02", "completion_date": "2013-11", "has_results": false, "last_update_posted_date": "2015-02-23", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445899" }, { "nct_id": "NCT01994291", "title": "A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Edema, Diabetic" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04634817", "type": "DRUG" }, { "name": "Masked Sham Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2013-11", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01994291" }, { "nct_id": "NCT00463320", "title": "A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Macular Degeneration", "Age-related Macular Degeneration" ], "interventions": [ { "name": "Pazopanib eye drops and Allergen Refresh Plus eye drops", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "30 Years to 55 Years" }, "enrollment_count": 29, "start_date": "2007-03", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2012-03-19", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 2, "location_summary": "Fargo, North Dakota • Austin, Texas", "locations": [ { "city": "Fargo", "state": "North Dakota" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00463320" }, { "nct_id": "NCT05714813", "title": "Circuit Training and Retina", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cognitive Impairment, Progressive", "Cerebral Small Vessel Diseases" ], "interventions": [ { "name": "High-Speed Circuit Resistance Training", "type": "BEHAVIORAL" }, { "name": "Lecture on Diet, Exercise and Cognition", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "65 Years to 90 Years" }, "enrollment_count": 40, "start_date": "2021-09-01", "completion_date": "2022-09-30", "has_results": false, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 2, "location_summary": "Coral Gables, Florida", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05714813" }, { "nct_id": "NCT02559180", "title": "Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Retinopathy", "Macular Edema" ], "interventions": [ { "name": "aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rishi Singh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-10", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559180" }, { "nct_id": "NCT01198327", "title": "Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Retinal Vein Occlusion" ], "interventions": [ { "name": "ranibizumab", "type": "DRUG" }, { "name": "Peripheral Laser", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Peter A Campochiaro, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-08", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-11-12T05:52:09.173Z", "location_count": 6, "location_summary": "Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Sacremento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01198327" } ] }